| __timestamp | BioCryst Pharmaceuticals, Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 8185000 |
| Thursday, January 1, 2015 | 13047000 | 8871000 |
| Friday, January 1, 2016 | 11253000 | 9645000 |
| Sunday, January 1, 2017 | 13933000 | 12387000 |
| Monday, January 1, 2018 | 29514000 | 14381000 |
| Tuesday, January 1, 2019 | 37121000 | 19238000 |
| Wednesday, January 1, 2020 | 67929000 | 17425000 |
| Friday, January 1, 2021 | 118818000 | 23040000 |
| Saturday, January 1, 2022 | 159371000 | 25116000 |
| Sunday, January 1, 2023 | 213894000 | 51953000 |
Data in motion
In the competitive world of biotechnology, strategic financial management is crucial. Over the past decade, CymaBay Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BioCryst's SG&A expenses surged by nearly 2800%, peaking in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, CymaBay's SG&A expenses grew by approximately 535% over the same period, indicating a more conservative growth strategy. Notably, in 2023, BioCryst's SG&A expenses were about four times higher than CymaBay's, highlighting their differing operational scales. These spending patterns offer insights into each company's strategic priorities and market positioning. As the biotech industry continues to evolve, understanding these financial dynamics is essential for investors and stakeholders alike.
Comparing SG&A Expenses: AstraZeneca PLC vs CymaBay Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.